Nasal Spray Treatment for Migraine Granted FDA Approval

January 30th 2019
Krista Rossi
Krista Rossi

The nasal spray is formulated using a proprietary novel excipient known as Intravail to achieve blood levels similar to a 4-mg sumatriptan subcutaneous injection, resulting in rapid onset of action.

The FDA has approved sumatriptan nasal spray (Tosymra,

Promius Pharma

) for the acute treatment of migraine with or without aura in adults.

The nasal spray is formulated using a proprietary novel excipient known as Intravail

to achieve blood levels similar to a 4-mg sumatriptan subcutaneous injection, resulting in rapid onset of action, according to Anil Namboodiripad, PhD, president of Promius Pharma.

Due to its formulation, the spray results in a rapid onset of action. Approximately 26% to 40% of migraine patients are not optimally controlled with their current treatment, according to independent research. A need for reliable and efficacious treatment options continues for patients who suffer from the debilitating and disruptive effects of migraine.

A version of this article was originally published by our sister publication Md Magazine. For more information, visitMdMag.com.

Related Content